Lysergide (LSD) interactions
Review the current reference classification for Lysergide (LSD) paired with medications or other agents represented in the Arcametric reference library.
Reference information only. This resource summarizes information from external sources and isn't individualized medical advice or a determination of treatment suitability.
Interactors with a reference entry
Antipsychotic
-
Lysergide (LSD) and Quetiapine (Seroquel) Possible Efficacy Blunting
Efficacy blunting and premature termination of therapeutic session from 5-HT2A and D2 antagonism. Risk of over-sedation and hypotension.
Evidence: Clinical trial, Observational
Benzodiazepine
-
Lysergide (LSD) and Diazepam (Valium) Possible Efficacy Blunting
Mild efficacy blunting and anxiety reduction from GABA-A positive allosteric modulation. Frequently used as a rescue medication.
Evidence: Observational, Guideline
Cardiovascular
-
Lysergide (LSD) and Propranolol Monitor Only
A historical clinical report (Lancet 1971) describes propranolol use for LSD-induced anxiety. Evidence is sparse. Bradycardia and bronchospasm risk from propranolol apply. Not appropriate as routine premedication.
Evidence: Linken 1971 Lancet (PMID 4108099) + FDA label (Inderal)
-
Lysergide (LSD) and Warfarin (Coumadin) Monitor Only
Theoretical bleeding risk from peripheral 5-HT2A antagonism on platelets. Largely theoretical with low evidence.
Evidence: Mechanistic theory only
GLP-1/GIP Agonist
-
Lysergide (LSD) and Zepbound (tirzepatide) Clinician Review
Delayed gastric emptying can shift LSD onset timing. Particularly high-leverage for LSD due to its long session duration — misinterpretation of non-response early in session magnifies dose-stacking risk.
Evidence: FDA label (Zepbound 2025) + mechanistic
SSRI/SNRI
-
Lysergide (LSD) and Fluoxetine (Prozac) Clinician Review
SSRIs typically reduce LSD effects due to 5-HT2A downregulation. Combination not recommended — unpredictable response.
-
Lysergide (LSD) and Pristiq (desvenlafaxine) Clinician Review
No direct LSD-desvenlafaxine pairing studies found. Mechanistic concern via Pristiq BP elevation and seizure warnings. Possible blunting via SNRI class effects.
Evidence: FDA label (Pristiq 2017) + mechanistic
Return to the Drug Interaction Checker to look up a specific pair, or open the Knowledge library.